Sam­sung Bi­o­log­ics is set to branch out to pep­tide in­gre­di­ent man­u­fac­tur­ing with plans to buy Swiss CD­MO PolyPep­tide for $1.8 bil­lion in cash.

The pur­chase...

Sar­to­rius ap­pears to be the first life sci­ence com­pa­ny to de­tail how tar­iff re­funds are af­fect­ing its rev­enue, fol­low­ing the US Supreme Court de­ci­sion to...

Pres­i­dent Don­ald Trump on Tues­day evening said he will im­pose up to 200% tar­iffs on gener­ic drugs sold in the US, if com­pa­nies do not man­u­fac­ture...

At least 10 House law­mak­ers are back­ing a US trade pan­el’s probe of Chi­na’s biotech sec­tor and re­lat­ed pric­ing prac­tices, en­cour­ag­ing fu­ture ex­ec­u­tive ac­tion.

In...

Plus, news about Lon­za, Bachem and Sam­sung Bi­o­log­ics. 

🤝 Repli­gen to ac­quire Bi­o­Life So­lu­tions: Repli­gen will pay around $1.5 bil­lionfor cell pro­cess­ing ser­vice sup­pli­er...

It’s no se­cret that sales of Leqem­bi have been dis­ap­point­ing.

First ap­proved in 2023, the Alzheimer’s drug from Ei­sai and Bio­gen launched short­ly af­ter Chris...

The FDA’s ap­provalfor Cel­cu­ity’s can­cer drug Revtor­pyk on Tues­day was wide­ly an­tic­i­pat­ed. What Wall Street didn’t ex­pect was that the drug could take un­til...